Skip to main content
Sangeetha Sagar

Sangeetha Sagar

Vice President, Product Development, International AIDS Vaccine Initiative 
United States

Sangeetha Sagar leads the International AIDS Vaccine Initiative’s (IAVI’s) efforts to rapidly advance the most promising vaccine and antibody candidates from the laboratory into clinical trials, accelerating the product development process.

Sangeetha has 29 years of experience in all aspects of chemistry, manufacturing and controls (CMC) development and supply of vaccines, gene and cell therapy products and mono and multi-specific antibodies and conjugates. Most recently, Sangeetha was the global head of biotherapeutics development and supply at Janssen, Johnson & Johnson, leading all aspects of end-to-end biotherapeutics development. Prior to that, she was at Sanofi Pasteur, leading quality, CMC innovation and the COVID-19 vaccine initiative for the company. She was at Merck & Co., Inc for 22 years, working in roles of increasing responsibility from “in the lab” to global leadership of BioProcess R&D for biologics.

Sangeetha has her PhD in chemical engineering from Carnegie Mellon University and was a John E. Fogarty NIH postdoctoral fellow at the CNRS in Marseille, France.

The IAS promotes the use of non-stigmatizing, people-first language. The translations are all automated in the interest of making our content as widely accessible as possible. Regretfully, they may not always adhere to the people-first language of the original version.